Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3
- 1 November 2000
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 6 (11) , 1258-1263
- https://doi.org/10.1038/81366
Abstract
In humans, sterile immunity against malaria can be consistently induced through exposure to the bites of thousands of irradiated infected mosquitoes. The same level of protection has yet to be achieved using subunit vaccines. Recent studies have indicated an essential function for intrahepatic parasites, the stage after the mosquito bite, and thus for antigens expressed during this stage. We report here the identification of liver-stage antigen 3, which is expressed both in the mosquito and liver-stage parasites. This Plasmodium falciparum 200-kilodalton protein is highly conserved, and showed promising antigenic and immunogenic properties. In chimpanzees (Pan troglodytes), the primates most closely related to humans and that share a similar susceptibility to P. falciparum liver-stage infection, immunization with LSA-3 induced protection against successive heterologous challenges with large numbers of P. falciparum sporozoites.Keywords
This publication has 31 references indexed in Scilit:
- Malaria VaccinesParasitology Today, 2000
- Cytotoxic T-Lymphocyte Epitopes for HLA-B53 and Other HLA Types in the Malaria Vaccine Candidate Liver-Stage Antigen 3Infection and Immunity, 2000
- Chromosome 2 Sequence of the Human Malaria ParasitePlasmodium falciparumScience, 1998
- Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzeesEuropean Journal of Immunology, 1997
- A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine againstPlasmodium falciparumMalariaNew England Journal of Medicine, 1997
- Synthesis and immunological characterization of 104-mer and 102-mer peptides corresponding to the N- and C-terminal regions of the Plasmodium falciparum CS proteinMolecular Immunology, 1995
- Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans.Journal of Clinical Investigation, 1995
- Crossreactive antigens between life cycle stages ofplasmodium faiciparumParasitology Today, 1992
- Protection against malaria induced by irradiated sporozoitesThe Lancet, 1990
- A liver-stage-specific antigen of Plasmodium falciparum characterized by gene cloningNature, 1987